HAHaider Ali

Haider Ali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haider Ali has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Corrigendum "Ferroptosis and circular RNAs: new horizons in cancer therapy"

    by Asif Ahmad Bhat, Neelima Kukreti, Muhammad Afzal, Ahsas Goyal, Riya Thapa, Haider Ali, Moyad Shahwan, Waleed Hassan Almalki, Imran Kazmi, Sami I. Alzarea, et al.

    EXCLI Journal - Experimental and Clinical Sciences, International Online Journal for Advances in Sciences

  • Open Access

    Ubiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance

    by Prasanna Srinivasan Ramalingam, Mohammad Afzal, Manjunath Mirle Rekha, Samir Sahoo, Surya Nath Pandey, Chandana Maji, Kavita Goyal, Haider Ali, Sachin Kumar Singh, Gaurav Gupta, et al.

    Ubiquitination and deubiquitination are biological mechanisms that including the addition and removal ubiquitin molecules from proteins, which are associated with NSCLC. NSCLC is the most common kind of lung cancer, and treatment resistance and cancer development are linked to these alterations. Ubiquitination incorporates proteins by a particular enzyme class, and deubiquitination removes ubiquitins. In NSCLC, this modification is detrimental to cellular function and affects tumorigenesis, apoptosis, and signaling pathways. Conversely, deubiquitination refers to the process through which the ubiquitins are removed from the proteins so that they can perform their functions properly. These processes can be considered therapeutic in some sense, as regulating both can result in an effective therapy for NSCLC. Many studies have been carried out to find potential areas where further drug research could be focused. This study examines the functions of ubiquitination and deubiquitination in NSCLC pathogenesis and resistance, focusing on their mechanisms, consequences, and therapeutic possibilities. Graphical Abstract

  • Non-coding RNA biomarkers in basal-like breast cancer

    by Haider Ali, Nawaid Hussain Khan, Dalila Cano, Guadalupe Cano, Meliha Celik, Sama Lilo, Angel Fabia, A. Yama, Efrain Gudino, Beyza Nur Beker


  • Open Access

    Parthanatos and apoptosis: unraveling their roles in cancer cell death and therapy resistance

    by Gaurav Gupta, Muhammad Afzal, Ehssan Moglad, Ahsas Goyal, Waleed Hassan Almalki, Kavita Goyal, Mohit Rana, Haider Ali, Arcot Rekha, Imran Kazmi, et al.

    Cell death is a fundamental process that needs to be maintained to balance cellular functions and prevent disease. There are several cell death pathways; however, apoptosis and parthanatos are the most prominent and have important roles in cancer biology. As an extremely well-regulated process, apoptosis removes damaged or abnormal cells via caspase activation and mitochondrial involvement. Unlike in the healthy cells, the loss of ability to induce apoptosis in cancer permits tumor cells to survive and multiply out of control and contribute to tumor progression and therapy resistance. On the contrary, parthanatos is a caspase-independent metabolic collapse driven by poly (ADP-ribose) polymerase 1 (PARP1) overactivation, translocation of apoptosis-inducing factor (AIF), and complete DNA damage. Several cancer models are involved with parthanatos. Deoxypodophyllotoxin (DPT) induces parthanatos in glioma cells by excessive ROS generation, PARP1 upregulation, and AIF nuclear translocation. Like in acute myeloid leukemia (AML), the cannabinoid derivative WIN-55 triggers parthanatos, and the effects can be reversed by PARP inhibitors such as olaparib. Developing cancer treatment strategies involving advanced cancer treatment strategies relies on the interplay between apoptosis and parthanatos. However, such apoptosis-based cancer therapies tend to develop resistance, so there is an urgent need to look into alternative pathways like parthanatos, which may not always trigger apoptosis. In overcoming apoptosis resistance, there is evidence that combining apoptosis-inducing agents, such as BH3 mimetics, with PARP inhibitors synergistically enhances cell death. Oxidative stress modulators have been found to promote the execution of parthanatic and apoptotic pathways and allow treatment. In this review, apoptosis and parthanatos are thoroughly compared at the molecular level, and their roles in cancer pathogenesis as related to cancer therapeutic potential are discussed. We incorporate recent findings to demonstrate that not only can parthanatos be used to manage therapy resistance and enhance cancer treatment via the combination of parthanatos and apoptosis but also that immunity and bone deposition can feasibly be employed against long-circulating cancer stem cells to treat diverse forms of metastatic cancers.


  • Liquid biopsies and exosomal ncRNA: Transforming pancreatic cancer diagnostics and therapeutics

    by Ashok Kumar Balaraman, Ehssan Moglad, Muhammad Afzal, M Arockia Babu, Kavita Goyal, R. Roopashree, Irwanjot Kaur, Sachin Kumar, Mravi Kumar, Ashish Singh Chauhan, et al.


  • ANRIL's Epigenetic Regulation and Its Implications for Cardiovascular Disorders

    by Ehssan Moglad, Parjinder Kaur, Soumya V. Menon, Abida, Haider Ali, Mandeep Kaur, Mahamedha Deorari, Kumud Pant, Waleed Hassan Almalki, Imran Kazmi, et al.

    Cardiovascular disorders (CVDs) are a major global health concern, but their underlying molecular mechanisms are not fully understood. Recent research highlights the role of long noncoding RNAs (lncRNAs), particularly ANRIL, in cardiovascular development and disease. ANRIL, located in the human genome's 9p21 region, significantly regulates cardiovascular pathogenesis. It controls nearby tumor suppressor genes CDKN2A/B through epigenetic pathways, influencing cell growth and senescence. ANRIL interacts with epigenetic modifiers, leading to altered histone modifications and gene expression changes. It also acts as a transcriptional regulator, impacting key genes in CVD development. ANRIL's involvement in cardiovascular epigenetic regulation suggests potential therapeutic strategies. Manipulating ANRIL and its associated epigenetic modifiers could offer new approaches to managing CVDs and preventing their progression. Dysregulation of ANRIL has been linked to various cardiovascular conditions, including coronary artery disease, atherosclerosis, ischemic stroke, and myocardial infarction. This abstract provides insights from recent research, emphasizing ANRIL's significance in the epigenetic landscape of cardiovascular disorders. By shedding light on ANRIL's role in cellular processes and disease development, the abstract highlights its potential as a therapeutic target for addressing CVDs.


  • Epithelial–mesenchymal transition to mitigate age-related progression in lung cancer

    by Riya Thapa, Saurabh Gupta, Gaurav Gupta, Asif Ahmad Bhat, Smriti, Madhav Singla, Haider Ali, Sachin Kumar Singh, Kamal Dua, Manoj Kumar Kashyap


  • CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications

    by Riya Thapa, Asif Ahmad Bhat, Gaurav Gupta, S. Renuka Jyothi, Irwanjot Kaur, Sachin Kumar, Naveen Sharma, G. V. Siva Prasad, Atreyi Pramanik, Haider Ali

    Cereblon (CRBN), a member of the E3 ubiquitin ligase complex, has gained significant attention as a therapeutic target in cancer. CRBN regulates the degradation of various proteins in cancer progression, including transcription factors and signaling molecules. PROTACs (proteolysis‐targeting chimeras) are a novel approach that uses the cell's degradation system to remove disease‐causing proteins selectively. CRBN‐dependent PROTACs work by tagging harmful proteins for destruction through the ubiquitin–proteasome system. This strategy offers several advantages over traditional protein inhibition methods, including the potential to overcome drug resistance. Recent progress in developing CRBN‐based PROTACs has shown promising preclinical results in both hematologic malignancies and solid tumors. Additionally, CRBN‐based PROTACs have enhanced our understanding of CRBN's role in cancer, potentially serving as biomarkers for patient stratification and predicting therapeutic responses. In this review, we delineate the mechanisms of action for CRBN‐dependent PROTACs (CRBN‐PROTACs), summarize recent advances in preclinical and clinical applications, and provide our perspective on future development.


  • Exploring ncRNAs in epilepsy: From oxidative stress regulation to therapy

    by Kumud Pant, Aanchal Sharma, Soumya V. Menon, Haider Ali, Waleed Hassan Almalki, Mandeep Kaur, Mahamedha Deorari, Imran Kazmi, Shriya Mahajan, Hitesh Kalra, et al.


  • Open Access

    Ferroptosis and circular RNAs

    by Asif Ahmad Bhat, Neelima Kukreti, Muhammad Afzal, Ahsas Goyal, Riya Thapa, Haider Ali, Moyad Shahwan, Waleed Hassan Almalki, Imran Kazmi, Sami I. Alzarea, et al.

    Cancer poses intricate challenges to treatment due to its complexity and diversity. Ferroptosis and circular RNAs (circRNAs) are emerging as innovative therapeutic avenues amid the evolving landscape of cancer therapy. Extensive investigations into circRNAs reveal their diverse roles, ranging from molecular regulators to pivotal influencers of ferroptosis in cancer cell lines. The results underscore the significance of circRNAs in modulating molecular pathways that impact crucial aspects of cancer development, including cell survival, proliferation, and metastasis. A detailed analysis delineates these pathways, shedding light on the molecular mechanisms through which circRNAs influence ferroptosis. Building upon recent experimental findings, the study evaluates the therapeutic potential of targeting circRNAs to induce ferroptosis. By identifying specific circRNAs associated with the etiology of cancer, this analysis paves the way for the development of targeted therapeutics that exploit vulnerabilities in cancer cells. This review consolidates the existing understanding of ferroptosis and circRNAs, emphasizing their role in cancer therapy and providing impetus for ongoing research in this dynamic field.